S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:ATRS

Antares Pharma Stock Forecast, Price & News

$3.26
+0.11 (+3.49%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.12
$3.27
50-Day Range
$3.15
$3.92
52-Week Range
$3.11
$5.07
Volume
595,574 shs
Average Volume
882,299 shs
Market Capitalization
$554.34 million
P/E Ratio
8.58
Dividend Yield
N/A
Beta
1.53
30 days | 90 days | 365 days | Advanced Chart
Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter.


Antares Pharma logo

About Antares Pharma

Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ATRS
CUSIP
03664210
Employees
185
Year Founded
N/A

Sales & Book Value

Annual Sales
$149.60 million
Cash Flow
$0.08 per share
Book Value
$0.83 per share

Profitability

Net Income
$56.20 million
Pretax Margin
12.42%

Debt

Price-To-Earnings

Miscellaneous

Free Float
160,010,000
Market Cap
$554.34 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/01/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

160th out of 1,390 stocks

Surgical & Medical Instruments Industry

20th out of 126 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 3.1 5 -4 -3 -2 -1 -












Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

Is Antares Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Antares Pharma stock.
View analyst ratings for Antares Pharma
or view top-rated stocks.

How has Antares Pharma's stock price been impacted by COVID-19?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRS stock has increased by 8.7% and is now trading at $3.26.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Antares Pharma?

Antares Pharma saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,660,000 shares, a decline of 34.2% from the October 31st total of 4,040,000 shares. Based on an average trading volume of 607,000 shares, the short-interest ratio is presently 4.4 days. Currently, 1.6% of the company's stock are sold short.
View Antares Pharma's Short Interest
.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Antares Pharma
.

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) announced its quarterly earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to analysts' expectations of $48.52 million. Antares Pharma had a trailing twelve-month return on equity of 14.44% and a net margin of 36.23%. During the same quarter in the prior year, the business posted $0.03 EPS.
View Antares Pharma's earnings history
.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180 million-$190 million, compared to the consensus revenue estimate of $186.50 million.

What price target have analysts set for ATRS?

4 brokerages have issued 12-month price targets for Antares Pharma's stock. Their forecasts range from $5.00 to $7.00. On average, they expect Antares Pharma's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 99.4% from the stock's current price.
View analysts' price targets for Antares Pharma
or view top-rated stocks among Wall Street analysts.

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Robert F. Apple, President, Chief Executive Officer & Director
  • Patrick Madsen, Senior Vice President-Operations
  • Fred M. Powell, Chief Financial Officer & Executive Vice President
  • Jonathan S. Jaffe, Vice President-Clinical & Medical Affairs
  • Peter C. Richardson, Chief Medical Officer & Executive VP-Research

What is Paul K. Wotton's approval rating as Antares Pharma's CEO?

5 employees have rated Antares Pharma CEO Paul K. Wotton on Glassdoor.com. Paul K. Wotton has an approval rating of 18% among Antares Pharma's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.99%), Rubric Capital Management LP (5.88%), Geode Capital Management LLC (1.68%), Putnam Investments LLC (1.03%), Dimensional Fund Advisors LP (0.98%) and Two Sigma Advisers LP (0.69%). Company insiders that own Antares Pharma stock include Anton Gueth, Fred M Powell, Leonard S Jacob, Marvin Samson, Peter J Graham, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma
.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Two Sigma Investments LP, Millennium Management LLC, Two Sigma Advisers LP, Assenagon Asset Management S.A., Janus Henderson Group PLC, and Virginia Retirement Systems ET AL. Company insiders that have sold Antares Pharma company stock in the last year include Anton Gueth, Leonard S Jacob, Peter J Graham, Robert F Apple, and Thomas J Garrity.
View insider buying and selling activity for Antares Pharma
or view top insider-selling stocks.

Which major investors are buying Antares Pharma stock?

ATRS stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Rubric Capital Management LP, Tocqueville Asset Management L.P., Russell Investments Group Ltd., Renaissance Technologies LLC, Stonepine Capital Management LLC, Dimensional Fund Advisors LP, and BlackRock Inc..
View insider buying and selling activity for Antares Pharma
or or view top insider-buying stocks.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $3.26.

How much money does Antares Pharma make?

Antares Pharma has a market capitalization of $554.34 million and generates $149.60 million in revenue each year. The specialty pharmaceutical company earns $56.20 million in net income (profit) each year or $0.38 on an earnings per share basis.

How many employees does Antares Pharma have?

Antares Pharma employs 185 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

Where are Antares Pharma's headquarters?

Antares Pharma is headquartered at 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at (609) 359-3020, via email at [email protected], or via fax at 302-655-5049.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.